Zein-Based Zinc Oxide Nanoparticles for Metformin Encapsulation: Synthesis, Characterization, and Biological Applications.
Biomedicine · 17.09.2026 · 46 (3) · 227-239
DOI: 10.51248/v46i3.70 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedicine, online erschienen am 17.09.2026. Verfasst von Santosh Mallikarjun Bhavi und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Aim: Type 2 diabetes mellitus (T2DM) remains a major global health challenge requiring improved drug delivery strategies. Zein, a maize-derived biopolymer, has attracted attention as a drug carrier because of its biocompatibility and controlled-release properties. This study aimed to synthesize zein-based zinc oxide nanoparticles (Zein-ZnONPs), characterize their physicochemical properties, evaluate their biological activities, and investigate their potential for metformin hydrochloride delivery. Materials and Methods: Zein-ZnONPs were synthesized using a solution combustion approach and characterized by UV-Vis spectroscopy, Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), dynamic light scattering (DLS), zeta potential analysis, and scanning electron microscopy (SEM). Metformin hydrochloride was encapsulated into the nanoparticles and evaluated by SEM and UV-Vis analysis. Antioxidant, anti-inflammatory, and antibacterial activities were assessed using DPPH radical scavenging, protein denaturation inhibition, and disc diffusion assays, respectively. Drug-release behavior was studied under simulated gastrointestinal conditions.
Results
Zein-ZnONPs exhibited particle sizes of 105-222 nm and a zeta potential of 4.5 mV. Characterization studies confirmed the formation of crystalline ZnO nanoparticles stabilized by zein. The nanoparticles showed concentration-dependent antioxidant activity with 95 DPPH inhibition at 100 μg mL¹ and anti-inflammatory activity with 90.7 inhibition of protein denaturation at 1000 μg mL¹. Moderate antibacterial activity was observed against the tested microorganisms. Metformin-loaded Zein-ZnONPs exhibited a biphasic drug-release profile with an estimated half-life of 7.7 h.
Conclusion
Zein-ZnONPs demonstrated favorable physicochemical properties, biological activities, and sustained drug-release behavior, indicating their potential as a nanocarrier for metformin delivery. Further studies are required to evaluate their therapeutic applicability in vivo.
Zitieren
APA
Bhavi, S. M., R2., R., V2., N. M., Mavinkar, S., R2., P., S2., C., Thokchom, B., Padti, A. C., Singh, S. R., Yarajarla, R. B., & Srinath, B. S. (2026). Zein-Based Zinc Oxide Nanoparticles for Metformin Encapsulation: Synthesis, Characterization, and Biological Applications. Biomedicine, 46(3), 227-239. https://doi.org/10.51248/v46i3.70
Vancouver
Bhavi SM, R2. R, V2. NM, Mavinkar S, R2. P, S2. C, et al. Zein-Based Zinc Oxide Nanoparticles for Metformin Encapsulation: Synthesis, Characterization, and Biological Applications. Biomedicine. 2026;46(3):227-239. doi:10.51248/v46i3.70
BibTeX
@article{Bhavi2026,
author = {Bhavi, Santosh Mallikarjun and R2., Rekha and V2., Naveen M. and Mavinkar, Sushmitha and R2., Pavithra and S2., Chandrakala and Thokchom, Bothe and Padti, Akshata Choudhari and Singh, Sapam Riches and Yarajarla, Ramesh Babu and Srinath, B. S.},
title = {Zein-Based Zinc Oxide Nanoparticles for Metformin Encapsulation: Synthesis, Characterization, and Biological Applications},
journal = {Biomedicine},
year = {2026},
volume = {46},
number = {3},
pages = {227--239},
doi = {10.51248/v46i3.70}
}
EUVIMED